Medical Aspects of Obesity

References

• Rosenbaum M., Leibel R. L., Hirsch J. Obesity. N Engl J Med, 1997, 337: 396-405.
   PubMed Web of Science ®Google Scholar
• Hubert H. B., Feinleib M., McNamara P. M., Castelli W. P. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation, 1983, 67: 968-77.
   PubMed Web of Science ®Google Scholar
• Jung R. T. Obesity as a disease. Br Med Bull, 1997, 53: 307-21.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer F. X. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther, 1996, 18: 1006-35.
   PubMed Web of Science ®Google Scholar
• Garrow J. S. Treatment of obesity. Lancet, 1992, 340: 409-13.
   PubMed Web of Science ®Google Scholar
• Scheen A. J., Desaive C., Lefêbvre P. J. Therapy for obesity — today and tomorrow. Baillière’s Clin Endocrinol Metab, 1994, 8: 705-27.
   PubMed Web of Science ®Google Scholar
• Chagnon Y. C., Pérusse L., Bouchard C. The human obesity gene map: the 1997 update. Obes Res, 1998, 6: 76-92.
   PubMedGoogle Scholar
• Kiberstis P. A., Marx J. (Eds). Regulation of body weight. Science, 1998, 280: 1363-90.
   Google Scholar
• Scheen A. J. Lessons from the discovery of leptin: is obesity an endocrine disease? Acta Clin Belg, 1996, 51: 371-6.
   PubMed Web of Science ®Google Scholar
• Friedman J. M. Leptin, leptin receptors, and the control of body weight. Nutr Rev, 1998, 56: S38-S46.
   PubMed Web of Science ®Google Scholar
• Reaven G. M. Role of insulin resistance in human disease. Diabetes, 1988, 37: 1595-607.
   PubMed Web of Science ®Google Scholar
• DeFronzo R. A., Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care, 1991, 14: 173-94.
   PubMed Web of Science ®Google Scholar
• Maggio C. A., Pi-Sunyer F. X. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care, 1997, 20: 1744-66.
   PubMed Web of Science ®Google Scholar
• Hafener S. M., Miettinen H. Insulin resistance implications for type II diabetes and coronary heart disease. Am J Med, 1997, 103: 152-62.
   Google Scholar
• Brown S. A., Upchurch S., Anding R., Winter M., Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care, 1996, 19: 613-24.
   PubMed Web of Science ®Google Scholar
• Scheen A. J. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab, 1998, 23: 116-23.
   Google Scholar
• Scheen A. J., Lefêbvre A. J. The management of the obese diabetic patient. Diabetes Rev, 1998; in press.
   Google Scholar
• Després J. P. Dyslipidaemia and obesity. Baillière’s Clin Endocrinol Metab, 1994, 8: 629-60.
   PubMed Web of Science ®Google Scholar
• Van Gaal L. F., Zhang A., Steijaert M. M., De Leeuw I. H. Human obesity: from lipid abnormalities to lipid oxidation. Int J Obesity, 1995, 19 (Suppl. 3): S21-6.
   Google Scholar
• Couillard C., Bergeron N., Prud’homme D. et al. Post-prandial triglyceride response in visceral obesity in men. Diabetes, 1998, 47: 953-60.
   PubMed Web of Science ®Google Scholar
• Muls E., VanSant G. Determinants of postprandial lipaemia in obesity. Int J Obesity, 1998, 22 (Suppl.) : in press.
   Google Scholar
• Datillo A., Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins : a meta-analysis. Am J Clin Nutr, 1992, 56: 320-8.
   PubMed Web of Science ®Google Scholar
• Huang Z., Willett W. C., Manson J. A. E. et al. Body weight, weight change, and risk for hypertension in women. Ann Intern Med, 1998, 128: 81-8.
   PubMed Web of Science ®Google Scholar
• Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities : the role of insulin resistance and the sympathoadrenal system. N Engl J Med, 1996, 334: 374-81.
   PubMed Web of Science ®Google Scholar
• Kolanowski J., Donkier J. Obesity and hypertension : from pathophysiology to treatment. Int J Obesity, 1998, 22 (Suppl.) : in press.
   Google Scholar
• Bonora E., Targhfr G., Zenere M. B. et al. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obesity, 1996, 20 : 975-80.
   PubMed Web of Science ®Google Scholar
• Le Devehat C., Khodabandehlou T., Dougny M. Etudes des paramètres hémorhéologiques dans l’obésité isolée. Diab Metab, 1992, 18 : 43-7.
   PubMed Web of Science ®Google Scholar
• Luyckx F. H., Scheen A. J., Desaive C., Dewé W., Gielen J. E., Lefêbvre P. J. Effects of gastroplasty on body weight and related biological abnormalities in morbid obesity. Diab Metab, 1998, 24 : 355-61.
   PubMed Web of Science ®Google Scholar
• Valensi P., Paries J., Maheo P. Erythrocyte Theological changes in obese patients : influence of hyperinsulinism. Int J Obesity, 1996, 20 : 814-9.
   Web of Science ®Google Scholar
• Luyckx F. H., Desaive C., Thiry A. et al. Liver abnormalities in severely obese subjects : effect of drastic weight loss after gastroplasty. Int J Obesity, 1998, 22 : 222-6.
   PubMed Web of Science ®Google Scholar
• Letiexhe M. R., Scheen A. J., Gérard P. L., Desaive C., Lefêbvre P. J. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab, 1995, 80: 393-9.
   PubMed Web of Science ®Google Scholar
• Scheen A., Henrivaux P., Scheen-Lavigne M., Jandrain B., Paquot N., Lefêbvre P. Les cures de jeûne modifié, protidique ou glucido-protidique, dans le traitement de l’obésité morbide. Med Nutr, 1988, 24 : 157-64.
   Google Scholar
• Stock M., Munro J. Second European Congress on Obesity, satellite conference : very low calorie diets. Int J Obesity, 1989, 13 (Suppl. 2): 1-199.
   Google Scholar
• Atkinson R. L., Pi-Sunyer F. X. Very-low-calorie diets. Proceedings of a Satellite Symposium to the 6th International Congress on Obesity. Am J Clin Nutr, 1992, 56 : 174S-305S.
   Web of Science ®Google Scholar
• Scheen A., Luyckx A. S., Scheen-Lavigne M., Lefèbvre P. J. Hormonal and metabolic adaptation to protein supplemented fasting in obese subjects. Int J Obesity, 1982, 6 : 165-74.
   PubMed Web of Science ®Google Scholar
• Bray G. A. Pharmacological treatment of obesity. In: Bray G. A., Bouchard C., James W. P. T. (eds). Handbook of obesity. New York-Basel-Hong Kong, M. Dekker, 1998: 953-75.
   Google Scholar
• Finer N. Present and future pharmacological approaches. Br Med Bull, 1997, 53: 409-32.
   PubMed Web of Science ®Google Scholar
• Scheen A. J., Lefèbvre P. J. Pharmacological treatment of obesity : present status. Int J Obesity, 1998, 22 (Suppl.) : in press.
   Google Scholar
• Connolly H. M., Crary J. L., McGoon M. D. et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med, 1997, 337: 581-8.
   PubMed Web of Science ®Google Scholar
• Lean M. E. J. Sibutramine — a review of clinical efficacy. Int J Obesity, 1997, 21 (Suppl. 1): S30-6.
   Google Scholar
• Sjöström L., Rissanen A., Andersen T. et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet, 1998, 352 : 167-73.
   PubMed Web of Science ®Google Scholar
• Desaive C. A critical review of a personal series of 1000 gastroplasties. Int J Obesity, 1995, 19 (Suppl. 3) : S56-60.
   Google Scholar